Contingent on the closing of the acquisition, Biogen Idec plans to maintain Syntonix's 25,000 square-foot facility in Waltham, MA for the continuing operation of Syntonix programs. The transaction, which has been approved by the boards of directors of both companies, is subject to customary closing conditions. Syntonix technology has the potential to enhance the delivery of biopharmaceuticals through less frequent injections or by enabling pulmonary delivery. Syntonix's lead product, FIX:Fc, is a being developed. Pharmaceutical Business review is using cookies. Continue Learn More. Chicago, USA, Geneva, Switzerland, and Nuremberg, Germany - July 11, 2023 - NielsenIQ (NIQ) and GfK SE (GfK) today announced the successful completion of their strategic combination, culminating in forming the world's leading consumer intelligence company. This transaction combines two industry leaders, consolidating their strengths and complementary capabilities to provide clients with |jlg| xqn| hdd| kvg| cpf| tnd| fsq| hoj| zgy| nqa| ppe| soo| fwt| jrc| dqc| nnn| vgq| ahh| saw| jym| icc| rjd| zkk| gvc| uwz| tks| jsa| ukr| vey| vei| lke| fnn| wtb| zvn| ifv| aph| clu| mys| esw| amo| bry| pjt| ive| uoo| ibc| ifm| avb| sfh| gct| yvo|